The Numbers (FY2025)

Consolidated MCR: 91.7% vs 89.1% in FY2024 (+260bps)

Every segment above target:

Marketplace exploded. From profitable (75.4%) to barely breakeven (90.6%) in one year. Management attributes this to:

• Higher utilization vs risk adjustment revenue
• Special Enrollment Period bringing high-acuity members
• ConnectiCare acquisition drag (closed Feb 1, 2025)
• CMS program integrity disenrollments (MOH covered medical costs for members who got kicked off)

Sensitivity: 1ppt MCR change = $6.20/share EPS impact. The 260bps consolidated swing effectively wiped ≈$16/share in earnings power.

Net income: $472M ($8.92/share) vs $1,179M ($20.42/share) in 2024 Operating income: $781M vs $1,707M (cut in half)

Cash Flow Went Deeply Negative

Operating cash flow: -$535M in 2025 vs +$644M in 2024. A $1.18B swing.

They liquidated $657M in investments to fund operations. Parent company cash dropped from $445M to $223M despite issuing $850M in new notes (Nov 20, 2025 credit agreement refinancing).

They burned $1B on buybacks during 2025 at prices far above current levels. Stock now trading ≈$125.

Covenant Amendment (Red Flag)

February 4, 2026 - six days before filing this 10-K - MOH amended its credit agreement to temporarily reduce the minimum Interest Coverage Ratio from 3.0x to 1.75x through Q4 2026, stepping back up gradually:

• Q1-Q4 2026: 1.75x (vs normal 3.0x)
• Q1 2027: 2.00x
• Q2 2027: 2.50x
• Q3 2027: 2.75x
• Q4 2027+: Back to 3.0x

This is covenant relief because profitability cratered so badly they couldn't maintain the 3x coverage threshold. Long-term debt: $3.77B (up from $2.92B).

What Drove the MCR Blowout

Medicaid (+150bps to 91.8%):

• Higher medical trend from utilization increases "higher than we expected"
• Changes in member acuity and product mix
• Increased behavioral health services, high-cost drugs, LTSS
• Broader utilization pressure in inpatient/outpatient
• Unfavorable retroactive premium items in California (Q4 2025)
• "Rate increases have lagged the increase in medical cost trend, resulting in a rate and trend imbalance that we believe to be temporary"

Medicare (+330bps to 92.4%):

• 10-K doesn't provide detailed breakdown, but notes the MCR increase
• Medicare membership grew 8% to 262K members
• Premium revenue up 13% to $6.2B

Marketplace (+1,520bps to 90.6%):

• As detailed above - catastrophic deterioration
• Membership more than doubled (703K vs 292K) due to ConnectiCare acquisition
• Premium revenue up 79% to $4.5B, but margin collapsed

OBBBA Structural Headwind

The One Big Beautiful Bill Act (signed July 2025) drives a 15-20% reduction on 1.2 million Medicaid Expansion members by 2029 via:

• Work requirements
• More frequent redeterminations
• Cost sharing

That's 180K-240K members lost over 2-3 years. But the acuity shift matters more: healthier members leave, sicker members stay, MCR worsens.

Law also reduces state provider tax revenue and limits provider payments - squeezing the entire Medicaid ecosystem. Marketplace subsidies also reduced (expiration in 2025 noted as headwind).

This is a second disruption wave stacking on top of the first wave (post-COVID redetermination acuity shift that's already crushing 2024-2025 results).

The Franchise (What Still Works)

5.5M members, 21 states, $43B premium revenue

RFP win rates remain strong:

• 90% Medicaid re-procurement win rate on $14B retained revenue
• 80% new contract win rate on $20B in premium
• $9B in incremental annual premium from 2025 RFP wins and acquisitions

New contracts started in 2026:

• Idaho (Medicaid + Medicare) - Jan 1
• Michigan (Medicare) - Jan 1
• Massachusetts (Medicare) - Jan 1
• Florida Medicaid - Feb 1 (awarded July 2024, commenced Feb 2025)

Growth engine still functioning despite profitability crisis. Revenue up 11% YoY, on track to exceed $50B by 2027 per management's stated target.

What the 10-K Says (And Doesn't Say)

Management's framing:

"The Medicaid MCR for 2025 is higher than we expected and is above our long-term target range."

"Rate increases have lagged the increase in medical cost trend, resulting in a rate and trend imbalance that we believe to be temporary."

This is the bull case embedded in the filing: Rate catch-up thesis. Rates will eventually adjust to the new higher cost base because of actuarial soundness requirements.

What's NOT in the 10-K:

• Forward guidance (that's in the Feb 5, 2026 8-K)
• Specific 2026 outlook or "trough year" narrative
• Cross-company comparison to peers

What IS visible:

• Covenant relief was needed (Feb 4 amendment)
• Cash flow went deeply negative (-$535M)
• They're liquidating investments to fund operations
• MCR deterioration was universal (all three segments)
• Management admits utilization was "higher than we expected"
• They explicitly call the rate/trend imbalance "temporary" (judgment call, not fact)

The Central Question

Is this structural or cyclical?

The 10-K provides evidence for both interpretations:

Cyclical signals:

• "Rate and trend imbalance that we believe to be temporary"
• Historical precedent: Medicaid rates do catch up (actuarial soundness requirement)
• RFP win rates remain strong (franchise intact)
• Revenue growth continuing (+11% YoY)

Structural signals:

• Covenant relief needed (couldn't maintain 3x coverage)
• Negative operating cash flow ($1.18B swing)
• Liquidating investments to fund operations
• OBBBA creates second wave (2027-2029) before first wave resolves
• Marketplace deterioration was extreme (75.4% → 90.6%)
• Universal MCR blowout (not isolated to one segment)

The 10-K doesn't resolve this. It documents the damage and management's belief that it's temporary.

Why This Matters

MOH filed for covenant relief 6 days before filing this 10-K. That's the smoking gun.

If management truly believed the MCR blowout was temporary and rates would catch up in 2026, why amend the credit agreement to reduce coverage requirements through all of 2026 and most of 2027?

The amendment schedule (1.75x → 2.0x → 2.5x → 2.75x → 3.0x) suggests they expect gradual recovery, not rapid snapback.

The financing stress is real. Negative cash flow, investment liquidation, and covenant relief don't happen to companies with "temporary" problems.

What To Watch

1. Q1 2026 results (will be in May 2026 8-K) - Does MCR stabilize or deteriorate further?
2. State rate announcements for 2027 cycle (typically mid-2026) - Evidence of rate catch-up velocity
3. Operating cash flow - Does it return positive or stay negative?
4. Peer 10-Ks - Is this MOH-specific or sector-wide? (CNC, HUM, UNH, ELV for comparison)

The 10-K documents the crisis. The resolution catalyst hasn't arrived yet.